PSA and hK2 in the diagnosis of prostate cancer;PSA y hK2 en el diagnóstico de cáncer de próstata

Actas Urologicas Espanolas

Volumn 32, Issue 6, 2008, Pages 575-588

  Alapont Alacreu, J M ^a   Navarro Rosales, S ^a   Budia Alba, A ^a   Espana Furio F ^a   Morera Martinez F ^a   Jimenez Cruz J F ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

hK2; Prostate cancer; PSA

Indexed keywords

EID: 48049087034     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0210-4806(08)73891-9     Document Type: Article

References (110)

1. Martin BJ, Cheli CD, Sterling K, Ward M, Pollard S, Lifsey D, et al. Prostate specific antigen isoforms and human glandular kallikrein 2 - which offers the best screening performance in a predominantly black population?. J Urol. 2006;175(1):104-107.
2. Brawer MK. Screening for prostate cancer. Semin Surg Oncol. 2000;18(1):29-36.
3. Hara M, Koyanagi Y, Inoue T, Fukuyama T. [Some physicochemical characteristics of "-seminoprotein", an antigenic component specific for human seminal plasma. Forensic immunological study of body fluids and secretion. VII]. Nippon Hoigaku Zasshi. 1971;25(4):322-324.
4. Seregni E, Botti C, Ballabio G, Bombardieri E. Biochemical characteristics and recent biological knowledge on prostate-specific antigen. Tumori. 1996;82(1):72-77.
5. Digby M, Zhang XY, Richards RI. Human prostate specific antigen (PSA) gene: structure and linkage to the kallikrein-like gene, hGK-1. Nucleic Acids Res. 1989;17(5):2137.
6. Cleutjens KB, van Eekelen CC, van der Korput HA, Brinkmann AO, Trapman J. Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J Biol Chem. 1996;271(11):6379-88.
7. Henttu P, Liao SS, Vihko P. Androgens up-regulate the human prostate-specific antigen messenger ribonucleic acid (mRNA), but down-regulate the prostatic acid phosphatase mRNA in the LNCaP cell line. Endocrinology. 1992;130(2):766-772.
8. Shan JD, Porvari K, Ruokonen M, Karhu A, Launonen V, Hedberg P, et al. Steroid-involved transcriptional regulation of human genes encoding prostatic acid phosphatase, prostate-specific antigen, and prostate-specific glandular kallikrein. Endocrinology. 1997;138(9):3764-3770.
9. Wang MC, Papsidero LD, Kuriyama M, Valenzuela LA, Murphy GP, Chu TM. Prostate antigen: a new potential marker for prostatic cancer. Prostate. 1981;2(1):89-96.
10. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145(5):907-23.
11. Graves HC. Nonprostatic sources of prostate-specific antigen: a steroid hormone-dependent phenomenon?. Clin Chem. 1995;41(1):7-9.
12. Wang MC, Papsidero LD, Chu TM. Prostate-specific antigen, p30, gamma-seminoprotein, and E1. Prostate. 1994;24(2):107-110.
13. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest. 1985;76(5):1899-1903.
14. Lilja H, Oldbring J, Rannevik G, Laurell CB. Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. J Clin Invest. 1987;80(2):281-285.
15. McGee RS, Herr JC. Human seminal vesicle-specific antigen is a substrate for prostate-specific antigen (or P-30). Biol Reprod. 1988;39(2):499-510.
16. Fortier AH, Nelson BJ, Grella DK, Holaday JW. Antiangiogenic activity of prostate-specific antigen. J Natl Cancer Inst. 1999; 91(19):1635-1640.
17. Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular scrine proteinase inhibitors. Eur J Biochem. 1990;194(3):755-763.
18. Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson O, Pettersson K, et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem. 1991;37(9):1618-1625.
19. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. 1991;51(1):222-226.
20. Vessella RL, Lange PH. Issues in the assessment of prostate-specific antigen immunoassays. An update. Urol Clin North Am. 1997;24(2):261-268.
21. McCormack RT, Rittenhouse HG, Finlay JA, Sokoloff RL, Wang TJ, Wolfert RL, et al. Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology. 1995;45(5):729-744.
22. Mettlin CJ, Murphy GP, Ho R, Menck HR. The National Cancer Data Base report on longitudinal observations on prostate cancer. Cancer. 1996;77(10):2162-2166.
23. Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA, et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol. 1992; 147(3 Pt 2):815-816.
24. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317(15):909-16.
25. Seaman E, Whang M, Olsson CA, Katz A, Cooner WH, Benson MC. PSA density (PSAD). Role in patient evaluation and management. Urol Clin North Am. 1993:20(4):653-663.
26. Catalona WJ, Richie JP, deKernion JB, Ahmann FR, Ratliff TL, Dalkin BL, et al. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. J Urol. 1994;152(6 Pt 1):2031-2036.
27. Brawer MK, Aramburu EA, Chen GL, Preston SD, Ellis WJ. The inability of prostate specific antigen index to enhance the predictive the value of prostate specific antigen in the diagnosis of prostatic carcinoma. J Urol. 1993;150(2 Pt 1):369-373.
28. Djavan B, Marberger M, Zlotta A, Schulman CC. PSA, f/t-PSA, PSAD, PSA-TZ, and PSA-velocity for prostate cancer prediction: a multivariate analysis. J Urol. 1998;159:235.
29. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. Jama. 1992; 267(16):2215-20.
30. Oesterling JE, Cooner WH, Jacobsen SJ, Guess HA, Lieber MM. Influence of patient age on the serum PSA concentration. An important clinical observation. Urol Clin North Am. 1993;20(4):671-680.
31. DeAntoni EP, Crawford ED, Oesterling JE, Ross CA, Berger ER, McLeod DG, et al. Age and race-specific reference ranges for prostate-specific antigen from a large community-based study. Urology. 1996;48(2):234-239.
32. Lein M, Koenig F, Jung K, McGovern FJ, Skates SJ, Schnorr D, et al. The percentage of free prostate specific antigen is an age-independent tumour marker for prostate cancer: establishment of reference ranges in a large population of healthy men. Br J Urol. 1998:82(2):231-236.
33. Morgan TO, Jacobsen SJ, McCarthy WF, Jacobson DJ, McLeod DG, Moul JW. Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med. 1996; 335(5):304-310.
34. Oesterling JE, Jacobsen SJ, Klee GG, Pettersson K, Piironen T, Abrahamsson PA, et al. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol. 1995;154(3):1090-1095.
35. Catalona WJ, Southwick PC, Slawin KM, Partin AW, Brawer MK, Flanigan RC, et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology. 2000;56(2):255-260.
36. Hofer C, Sauerstein P, Wolter C, Scholz M, Hartung R, Breul J. Value of free prostate-specific antigen (Hybritech Tandem-R) in symptomatic patients consulting the urologist. Urol Int. 2000;64(1):18-23.
37. Lilja H. Structure, function, and regulation of the enzyme activity of prostate-specific antigen. World J Urol. 1993;11(4):188-191.
38. Christerisson A, Bjork T, Nilsson O, Dahlen U, Matikainen MT, Cockett AT, et al. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol. 1993:150(1):100-105.
39. Woodrum DL, Brawer MK, Partin AW, Catalona WJ, Southwick PC. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol. 1998:159(1):5-12.
40. Okihara K, Ukimura O, Nakamura T, Mizutani Y, Kawauchi A, Naya Y, et al. Can complexed prostate specific antigen enhance prostate cancer detection in Japanese men?. Eur Urol. 2004;46(1):57-64.
41. Kobayashi T, Kamoto T, Nishizawa K, Mitsumori K, Ogura K, Ide Y. Prostate-specific antigen (PSA) complexed to alpha1-antichymotrypsin improves prostate cancer detection using total PSA in Japanese patients with total PSA levels of 2.0-4.0 ng/mL. BJU Int. 2005;95(6):761-765.
42. Okegawa T, Noda H, Nutahara K, Higashihara E. Comparisons of the various combinations of free, complexed, and total prostate-specific antigen for the detection of prostate cancer. Eur Urol. 2000;38(4):380-387.
43. Saika T, Tsushima T, Nasu Y, Kusaka N, Miyaji Y, Takamoto H, et al. Prostate specific antigen complexed to alpha-1-antichymotrypsin in patients with intermediate prostate specific antigen levels. Cancer. 2002;94(6):1685-1691.
44. Jung K, Brux B, Lein M, Knabich A, Sinha P, Rudolph B, et al. Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA. Urology. 1999;53(6):1160-1167; discussion 1167-1168.
45. España F, Martinez M, Sanchez-Cuenca J, Vera CD, Estelles A, Jimenez-Cruz JF. Prostate-specific antigen and its complexes with alpha 1-antichymotrypsin in the plasma of patients with prostatic disease. Eur Urol. 1996;30(4):512-518.
46. Martinez M, España F, Royo M, Aznar J, Vera CD, Estellés A, et al. Formas moleculares del PSA: ¿qué aportan al diagnóstico del cáncer de próstata? Urol Integr Invest. 1998;3:173-177.
47. España F, Royo M, Martinez M, Enguidanos MJ, Vera CD, Estelles A, et al. Free and complexed prostate specific antigen in the differentiation of benign prostatic, hyperplasia. and prostate cancer: studies in serum and plasma samples. J Urol. 1998;160(6 Pt 1):2081-2088.
48. Martinez M, España F, Royo M, Vera CD, Estelles A, Jimenez-Cruz JF, et al. Prostate-specific antigen complexed to alpha(1)-antichymotrypsin in the early detection of prostate cancer. Eur Urol. 2000;38(1):85-90.
49. Martinez M, España F, Royo M, Alapont JM, Navarro S, Estelles A, et al. The proportion of prostate-specific antigen (PSA) complexed to alpha(1)-antichymotrypsin improves the discrimination between prostate cancer and benign prostatic hyperplasia in men with a total PSA of 10 to 30 microg/L. Clin Chem. 2002:48(8):1251-1256.
50. Brawer MK, Cheli CD, Neaman IE, Goldblatt J, Smith C, Schwartz MK, et al. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol. 2000;163(5):1476-1480.
51. Partin AW, Brawer MK, Bartsch G, Horninger W, Taneja SS, Lepor H, et al. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol. 2003;170(5):1787-1791.
52. Sokoll LJ, Bruzek DJ, Cox JL. Is complexed PSA alone clinically useful?. J Urol. 1998; 159:895A.
53. Djavan B, Remzi M, Zlotta AR, Ravery V, Hammerer P, Reissigl A, et al. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial. Urology. 2002;60(4 Suppl 1):4-9.
54. Alapont Alacreu JM. Desarrollo y evaluación de nuevos marcadores diagnósticos y pronósticos en el cáncer de próstata [Tesis doctoral]. Valencia: Universidad de Valencia: 2007.
55. Okihara K, Cheli CD, Partin AW, Fritche HA, Chan DW, Sokoll LJ, et al. Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. J Urol. 2002;167(5):2017-2023; discussion 2023-2024.
56. Stamey TA, Yemoto CE. Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: relationship to transition zone volume. J Urol. 2000;163(1):119-126.
57. Parsons JK, Brawer MK, Cheli CD, Partin AW, Djavan R. Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6-4.0 ng/mL range of total PSA. BJU Int. 2004;94(1):47-50.
58. Lein M, Kwiatkowski M, Semjonow A, Luboldt HJ, Hammerer P, Stephan C, et al. A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations. J Urol. 2003;170(4 Pt 1):1175-1179.
59. Jung K, Stephan C, Elgeti U, Lein M, Brux B, Kristiansen G, et al. Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 microg/L: are they useful tools for early detection and screening of prostate cancer?. Int J Cancer. 2001;93(5):759-765.
60. Okihara K, Fritsche HA, Ayala A, Johnston DA, Allard WJ, Babaian RJ. Can complexed prostate specific antigen and prostatic volume enhance prostate cancer detection in men with total prostate specific antigen between 2.5 and 4.0 ng./ml. J Urol. 2001;165(6 Pt 1):1930-1936.
61. España F, Sanchez-Cuenca J, Estelles A, Gilabert J, Griffin JH, Heeb MJ. Quantitative immunoassay for complexes of prostate-specific antigen with alpha2-macroglobulin. Clin Chem. 1996;42(4):545-550.
62. Zhang WM, Finne P, Leinonen J, Vesalainen S, Nordling S, Rannikko S, et al. Characterization and immunological determination of the complex between prostate-specific antigen and alpha2-macroglobulin. Clin Chem. 1998;44(12):2471-2479.
63. Zhang WM, Finne P, Leinonen J, Salo J, Stenman UH. Determination of prostate-specific antigen complexed to alpha(2)-macroglobulin in serum increases the specificity of free to total PSA for prostate cancer. Urology. 2000;56(2):267-272.
64. Zhang WM, Finne P, Leinonen J, Vesalainen S, Nordling S, Stenman UH. Measurement of the complex between prostate-specific antigen and alphal-protease inhibitor in serum. Clin Chem. 1999;45(6 Pt 1):814-821.
65. Young CY, Andrews PE, Montgomery BT, Tindall DJ. Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein. Biochemistry. 1992;31(3):818-824.
66. Deperthes D, Chapdelaine P, Tremblay RR, Brunet C, Berton J, Hebert J, et al. Isolation of prostatic kalhkrein hK2, also known as hGK-1, in human seminal plasma. Biochim, Biophys Acta. 1995;1245(3):311-316.
67. Finlay JA, Evans CL, Day JR, Payne JK, Mikolajczyk SD, Millar LS, et al. Development of monoclonal antibodies specific for human glandular kallikrein (hK2): development of a dual antibody immurroassay for hK2 with negligible prostate-specific antigen cross-reactivity. Urology. 1998;51(5):804-809.
68. Wang TJ, Rittenhouse HG, Wolfert RL, Lynne CM, Brackett NL. PSA concentrations in seminal plasma. Clin Chem. 1998:44(4): 895-896.
69. Murtha P, Tindall DJ, Young CY. Androgen induction of a human prostate-specific kallikrein, hKLK2: characterization of an androgen response element in the 5′ promoter region of the gene. Biochemistry. 1993;32(25):6459-6464.
70. Mikolajczyk SD, Millar LS, Kumar A, Saedi MS. Human glandular kallikrein, hK2, shows arginine-restricted specificity and forms complexes with plasma protease inhibitors. Prostate. 1998;34(1):44-50.
71. Chapdelaine P, Paradis G, Tremblay RR, Dube JY. High level of expression in the prostate of a human glandular kallikrein mRNA related to prostate-specific antigen. FEBS Lett. 1988; 236(1):205-208.
72. Morris BJ. hGK-1: a kallikrein gene expressed in human prostate. Clin Exp Pharmacol Physiol. 1989;16(4):345-351.
73. Black MH, Magklara A, Obiezu CV, Melegos DN, Diamandis EP. Development of an ultrasensitive immurroassay for human glandular kallikrein with no cross-reactivity from prostate-specific antigen. Clin Chem. 1999;45(6 Pt 1):790-799.
74. Partin AW, Catalona WJ, Finlay JA, Darte C, Tindall DJ, Young CY, et al. Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis. Urology. 1999;54(5): 839-845.
75. Grauer LS, Finlay JA, Mikolajczyk SD, Pusateri KD, Wolfert RL. Detection of human glandular kallikrein, hK2, as its precursor form and in complex with protease inhibitors in prostate carcinoma serum. J Androl. 1998:19(4):407-411.
76. Darson MF, Pacelli A, Roche P, Rittenhouse HG, Wolfert RL, Young CY, et al. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology. 1997:49(6):857-862.
77. Tremblay RR, Deperthes D, Tetu B, Dube JY. Immunohistochemical study suggesting a complementary role of kallikreins hK2 and hK3 (prostate-specific antigen) in the functional analysis of human prostate tumors. Am J Pathol. 1997;150(2): 455-459.
78. Kumar A, Mikolajczyk SD, Goel AS, Millar LS, Saedi MS. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res. 1997;57(15):3111-3114.
79. Takayama TK, Fujikawa K, Davie EW. Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein. J Biol Chem. 1997;272 (34):21582-21588.
80. Saedi MS, Hill TM, Kuus-Reichel K, Kumar A, Payne J, Mikolajczyk SD, et al. The precursor form of the human kallikrein 2, a kallikrein homologous to prostate-specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasia. Clin Chem. 1998;44(10): 2115-2119.
81. Heeb MJ, España F. Alpha2-macroglobulin and C1-inactivator are plasma inhibitors of human glandular kallikrein. Blood Cells Mol Dis. 1998;24(4):412-419.
82. Charlesworth MC, Young CY, Klee GG, Saedi MS. Mikolajczyk SD, Finlay JA, et al. Detection of a prostate-specific protein, human glandular kallikrein (hK2), in sera of patients with elevated prostate-specific antigen levels. Urology. 1997:49(3):487-493.
83. Rittenhouse HG, Tindall DJ, Klee GG. Characterization and evaluation of hK2; A potential prostate cancer marker, closely related to PSA. Proceedings of the First International Consultation on Prostate Cancer. 1996.
84. Kwiatkowski MK, Recker F, Piironen T, Pettersson K, Otto T, Wernli M, et al. In prostatisin patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL. Urology. 1998;52(3):360-365.
85. Piironen T, Lovgren J, Karp M, Eerola R, Lundwall A, Dowell B, et al. Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum. Clin Chem. 1996;42(7):1034-1041.
86. Becker C, Piironen T, Pettersson K, Bjork T, Wojno KJ, Oesterling JE, et al. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum. J Urol. 2000;163(1):311-316.
87. Magklara A, Scorilas A, Catalona WJ, Diamandis EP. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. Chn Chem. 1999;45(11):1960-1966.
88. Recker F, Kwiatkowski MK, Pilronen T, Pettersson K, Lummen G, Wernli M, et al. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma. Cancer. 1998;83(12):2540-2547.
89. Becker C, Piironen T, Pettersson K, Hugosson J, Lilja H. Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater. Urology. 2000;55(5):694-699.
90. Nam RK. Diamandis EP, Toi A, Trachtenberg J, Magklara A, Scorilas A, et al. Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. J Clin Oncol. 2000;18(5): 1036-1042.
91. Darson MF, Pacelli A, Roche P, Rittenhouse HG, Wolfert RL, Saeid MS, et al. Human glandular kaWkrein 2 expression in prostate adenocarcinoma and lymph node metastases. Urology. 1999;53(5):939-944.
92. Corey E, Arfman EW, Oswin MM, Melchior SW, Tindall DJ, Young CY, et al. Detection of circulating prostate cells by reverse transcriptase-polymerase chain reaction of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) messages. Urology. 1997:50(2):184-188.
93. Stephan C, Jung K, Soosaipillai A, Yousef GM, Cammann H, Meyer H, et al. Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection. BJU Int. 2005;96(4):521-527.
94. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. Jama. 1995;274(15):1214-1220.
95. Morote J, Raventos CX, Lorente JA, Lopez-Pacios MA, Encabo G, de Torres I, et al. Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml. J Urol. 1997;158(2):502-504.
96. Bangma CH, Rietbergen JB, Kranse R, Blijenberg BG, Petterson K, Schroder FH. The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population, J Urol. 1997;157(6):2191-2196.
97. Brawer MK, Meyer GE, Letran JL, Bankson DD, Morris DL, Yeung KK, et al. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology. 1998;52(3):372-378.
98. Kuriyama M, Kawada Y, Arai Y, Maeda H, Egawa S, Koshiba K, et al. Significance of free to total PSA ratio in men with slightly elevated serum PSA levels: a cooperative study. Jpn J Clin Oncol. 1998;28(11):661-665.
99. Partin AW, Brawer MK, Subong EN, Kelley CA, Cox JL, Bruzek DJ, et al. Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer. Prostate Cancer Prostatic Dis. 1998:1(4):197-203.
100. Martinez-Pineiro L, Tabernero A, Contreras T, Madero R, Lozano D, Lopez-Tello J, et al. Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml. Eur Urol. 2000; 37(3):289-296.
101. Vessella RL, Lange PH, Partin AW, Chan DW, Sokoll W, Sasse EA, et al. Probability of prostate cancer detection based on results of a multicenter study using the AxSYM free PSA and total PSA assays. Urology. 2000;55(6):909-914.
102. Haese A, Dworschack RT, Partin AW. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range. J Urol. 2002;168(2): 504-508.
103. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. Jama. 1997;277(18): 1452-1455.
104. Prestigiacomo AF, Stamey TA. Can free and total prostate specific antigen and prostatic volume distinguish between men with negative and positive systematic ultrasound guided prostate biopsies?. J Urol. 1997;157(1):189-194.
105. Catalona WJ, Partin AW, Finlay JA, Chan DW, Rittenhouse HG, Wolfert RL, et al. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology. 1999;54(2):220-224.
106. Djavan B, Zlotta A, Kratzik C, Remzi M, Seitz C, Schulman CC, et al. PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL. Urology. 1999;54(3):517-522.
107. Roehl KA, Antenor JA, Catalona WJ. Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6 to 4.0 ng./ml. range. J Urol. 2002; 168(3):922-925.
108. Horninger W, Cheli CD, Babaian RJ, Fritsche HA, Lepor H, Taneja SS, et al. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter. Urology. 2002;60(4 Suppl 1):31-35.
109. Maeda H, Arai Y, Aoki Y, Okubo K, Okada T, Maekawa S. Complexed prostate-specific antigen and its volume indexes in the detection of prostate cancer. Urology. 1999;54(2):225-228.
110. Okegawa T, Noda H, Nutahara K, Higashihara E. Comparison of two investigative assays for the complexed prostate-specific antigen in total prostate-specific antigen between 4.1 and 10.0 ng/mL. Urology. 2000;55(5):700-704.